1946 – Foundation of Biotest Serum-Institut GmbH by Carl Adolf Schleussner and Dr. Hans Schleussner.
Initially the family enterprise focussed on research on blood typing serology.

1948 – The test serum anti-D for the determination of the rhesus factor is introduced world-wirde as one of the first products of this kind.

1949 – Production of the first plasma protein product, Biseko® 

1961 – Groundbreaking for the new production facilities at Dreieich. Follwed by gradual transfer of all activities from Frankfurt to Dreieich.

1968 – Foundation of a first European subsidiary in Italy.

1971 – Production of the first polyspecific immunoglobulin preparation.

1979 – Development of the first air sampler as the start of Biotest's Microbiological Diagnostic business
(hygiene monitoring).

1982 and 1983 – Market introduction of the hyper-immunoglobulin preparations Hepatect®, Cytotect®, and Varitect®

1985 – Market introduction of the first intravenously tolerable IgM-enriched immunoglobulin Pentaglobin®.

1986 – Reorganization of Biotest Serum-Institut GmbH to Biotest AG, advancing the expansion of the business divisions Pharmaceuticals and Diagnostics.

1987 – As a world-wide operating corporation, Biotest goes public at the Frankfurt Stock Exchange.

1993 – Production of the first double virus-inactivated factor VIII preparation (Haemoctin®) for hemophiliacs.

2004 – Start of operation of the extensively modernized pharmaceutical production facilty, followed by further additions to capacity (total investments over 80 Mio. €) - Market introduction of Intratect®.

2005 – Approval of the fully automated blood typing system TANGO and the corresponding regants for the US market.

2005 – Increase in capital of approx. 50 Mio. €

2007 – Beginning of clinical testings with new monoclonal antibodies.
        – Dec 4, 2007 Purchase of plasma protein business of Nabi Biopharmaceuticals Corp.
        – Dec 27, 2007 Biotest preference share listed in SDAX.        

2008 – Mar 11, 2008  Orphan drug designation granted for monoclonal antibody, BT-062, in the USA
         – Aug 18, 2008  FDA authorises marketing of manual reagents for blood group typing 
         – Dec 10, 2008  European approval for Haemonine® (Factor IX)
         – Dec 15, 2008  European Commission grants Orphan Drug designation to the monoclonal antibody BT-062
  
2009 –  Mar 19, 2009  Expansion of immunoglobulin production capacity from 2 to 4 tons
         –  30.11.2009 Marketing authorization Zutectra®

2010 –  6.1.2010 Sale of Medical Diagnostics business to Bio-Rad completed

2011 –  21.6.2011 Cooperation contract on Co-Development and Co-Marketing of monoclonal antibody
             BT-061 with Abbott Laboratories, Inc.
        –   1.8.2011 Sale of Microbiological Monitoring business to Merck KGaA completed